Size: 33 x 50 cm

Rainbow® Children's Hospital

It takes a lot to treat the little.

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

RAINBOW CHILDREN'S MEDICARE LIMITED

Our Company was originally incorporated as 'Rainbow Children's Medicare Private Limited' under the provisions of the Companies Act, 1956, as a private limited company, at Hyderabad, Telangana, pursuant to a certificate of incorporation dated August 7, 1998, issued by the Registrar of Companies, Hyderabad at Telangana ("**RoC**"). Subsequently, our Company was converted into a public limited company, and the name of our Company was changed to 'Rainbow Children's Medicare Limited' pursuant to a special resolution passed by the Shareholders of our Company on November 3, 2021 and a fresh certificate of incorporation was consequently issued by the RoC on November 20, 2021 under the Companies Act, 2013. For further details in relation to the changes to the name of our Company and the Registered Office, see "*History and Certain Corporate Matters*" on page 294 of the prospectus dated May 2, 2022 ("**Prospectus**").

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad – 500 034, Telangana, **Telephone:** + 91 40 49692244.
Corporate Office: 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad – 500 034, Telangana, **Telephone:** +91 40 49692244
Contact Person: Ashish Kapil, Company Secretary and Compliance Officer, **E-mail:** companysecretary@rainbowhospitals.in; **Website**: www.rainbowhospitals.in; **Corporate Identity Number**: U85110TG1998PLC029914

OUR PROMOTERS: DR. RAMESH KANCHARLA, DR. DINESH KUMAR CHIRLA AND DR. ADARSH KANCHARLA

Our Company has filed the Prospectus dated May 2, 2022 with the RoC and the Equity Shares are proposed to be listed on the National Stock Exchange of India Limited ("NSE") and the BSE Limited ("BSE") and the trading will commence on May 10, 2022.

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFERING OF 29,168,579 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF RAINBOW CHILDREN'S MEDICARE LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 542^ PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 532 PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING TO ₹ 15,808.49 MILLION (THE "OFFER"), COMPRISINGA FRESH ISSUE OF 5,167,679 EQUITY SHARES AGGREGATING TO ₹ 2,800 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF 24,000,900 EQUITY SHARES AGGREGATING TO ₹ 13,008.49 MILLION BY THE SELLING SHAREHOLDERS REFERRED TO IN ANNEXURE A ON PAGE 641 OF THE PROSPECTUS (THE "OFFER FOR SALE"). THE OFFER INCLUDED A RESERVATION OF UPTO 300,000 EQUITY SHARES AGGREGATING TO ₹ 156.60 MILLION (CONSTITUTING 0.30% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WOULD CONSTITUTE 28.74%* AND 28.69%*, RESPECTIVELY, OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL.

^OUR COMPANY, DR. RAMESH KANCHARLA (ACTING ON BEHALF OF THE OTHER PROMOTER SELLING SHAREHOLDERS AND THE OTHER SELLING SHAREHOLDER) AND THE INVESTOR SELLING SHAREHOLDERS, IN CONSULTATION WITH THE BRLMS, OFFERED A DISCOUNT OF ₹ 20 TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION.

***PLEASE NOTE THAT THE OFFER AND THE NET OFFER % HAS BEEN ADJUSTED FOR THE FRESH ISSUE OF 5,167,679 EQUITY SHARES AND ALLOTMENT TO ELIGIBLE EMPLOYEE OF 44,118 EQUITY SHARES IN THE OFFER RESPECTIVELY.**

OFFER PRICE: ₹ 542 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH

ANCHOR INVESTOR OFFER PRICE: ₹ 542 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH

THE OFFER PRICE IS 54.20 TIMES THE FACE VALUE OF THE EQUITY SHARES

Risks to Investors

- **The Offer Price is ₹542 per Equity Share. However, the average cost of acquisition per Equity Share for the Selling Shareholders is as follows:**

Name of the Selling shareholder	Avg. cost of acquisition per Equity Share as on the date of the RHP (in ₹)	Name of the Selling shareholder	Avg. cost of acquisition per Equity Share as on the date of the RHP (in ₹)
Dr. Ramesh Kancharla (Promoter Selling Shareholder)	7.32	Mrs. Padma Kancharla (Other Selling Shareholder)	Nil
Dr. Dinesh Kumar Chirla (Promoter Selling Shareholder)	0.91	British International Investment plc (formerly known as CDC Group plc) (Investor Selling Shareholder)	54.50
Dr. Adarsh Kancharla (Promoter Selling Shareholder)	Nil	CDC India (Investor Selling Shareholder)	110.29

- **Our revenues are highly dependent on our hospitals in Hyderabad and Bengaluru. Of our 14 hospitals, six are situated in Hyderabad, Telangana and three are situated in Bengaluru, Karnataka. Any impact on the revenues from these hospitals could materially affect our business, financial condition and results of operations. The proportion of volumes at hospitals in Hyderabad and Bengaluru, of our aggregate inpatient and outpatient volumes across all our hospitals are as follows:**

Particulars	Fiscal 2019	Fiscal 2020	Fiscal 2021	For the nine months period ended December 31, 2021
Proportion of volumes at hospitals in Hyderabad and Bengaluru to aggregate inpatient and outpatient volumes across all our hospitals	84.07%	81.89%	78.98%	77.28%

- **We are dependent on our medical professionals and our business and financial results could be impacted if we are not able to attract and retain such medical professionals. The attrition rate for our permanent employees, which includes nurses (including interns and paramedical personnel) are as follows :**

Particulars	Fiscal 2019	Fiscal 2020	Fiscal 2021	For the nine months period ended December 31, 2021
Attrition rate for our permanent employees, which includes nurses (including interns and paramedical personnel)	35.41%	38.75%	45.50%	26.74%

- **The Offer Price, market capitalization to revenue multiple and price to earnings ratio based on the Offer Price of our Company, may not be indicative of the market price of our Company on listing or thereafter. The details of our price to earnings ratio and market capitalization to revenue from operations based on the Offer Price i.e. ₹542 per Equity Share are given below:**

Particulars	Price to earnings ratio (based on diluted EPS)	Market capitalization to revenue
For the year ended March 31, 2021	127.53	7.91

For details of market capitalization to revenue multiple for our listed peers that have a similar business profile to us, please see "Basis for Offer Price" section at page 171 of the Prospectus.

- **Weighted average cost of acquisition of all shares transacted in last three years and one year preceding the date of the Prospectus:**

Period	Weighted Average Cost of Acquisition^ (in ₹)	Cap Price (₹ 542) is 'X' times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price - Highest Price^ (in ₹)
Last 1 year	7.80	69.49	0-70
Last 3 years	7.80	69.49	0-70

^As certified by Madhu Mantri and Associates, Chartered Accountants, in their certificate dated May 2, 2022.

- **We are significantly dependent on certain specialties for a majority of our revenues. We have four core specialties, namely secondary pediatric care, tertiary pediatric care, quaternary pediatric care and women care (gynecology, obstetrics and related services), of which our secondary pediatric care services have historically accounted for the largest portion of our revenues. See "Our Business – Key Specialties – Pediatric services (including secondary, tertiary and quaternary care)" on page 259 of the Prospectus.**

BID/OFFER PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: TUESDAY, APRIL 26, 2022

BID/OFFER OPENED ON: WEDNESDAY, APRIL 27, 2022

BID/OFFER CLOSED ON: FRIDAY, APRIL 29, 2022

The Offer was made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR, read with Regulation 31 of the SEBI ICDR Regulations, and in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Offer was available for allocation on a proportionate basis to Qualified Institutional Buyers ("**QIBs**", and such portion, the "**QIB Portion**"), provided that our Company, Dr. Ramesh Kancharla (acting on behalf of the other Promoter Selling Shareholders and the Other Selling Shareholder) and the Investor Selling Shareholders may, in consultation with the BRLMs, allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (the "**Anchor Investor Portion**"), of which one-third was reserved for domestic Mutual Funds, subject to valid Bids having been received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. Further, 5% of the Net QIB Portion was made available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion was made available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids having been received at or above the Offer Price. Further, not less than 15% of the Net Offer was made available for allocation to Non-Institutional Bidders ("**Non-Institutional Portion**") of which one-third of the Non-Institutional Portion was made available for allocation to Bidders with an application size of more than ₹ 200,000 and up to ₹ 1,000,000 and two-thirds of the Non-Institutional Portion was made available for allocation to Bidders with an application size of more than ₹ 1,000,000 and under-subscription in either of these two sub-categories of Non-Institutional Portion was allocated to Bidders in the other sub-category of Non-Institutional Portion, and not less than 35% of the Net Offer was made available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential Bidders, other than Anchor Investors, were required to mandatorily utilise the Application Supported by Blocked Amount ("**ASBA**") process by providing details of their respective ASBA accounts and UPI ID (in case of Retail Individual Bidders using UPI Mechanism), if applicable, in which the corresponding Bid Amounts was blocked by the self-certified syndicate banks ("**SCSBs**") or under the UPI Mechanism, as applicable, to participate in the Offer. Anchor Investors were not permitted to participate in the Anchor Investor Portion through the ASBA process. See "*Offer Procedure*" on page 523 of the Prospectus.

The bidding for Anchor Investor opened and closed on Tuesday, April 26, 2022. The Company received 36 applications from 23 anchor investors for 8,878,896 Equity Shares. The Anchor Investor Offer Price was finalized at ₹ 542 per Equity Share. A total of 8,663,404 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 4,695,564,968.

The Offer received 254,335 applications for 257,733,603 Equity Shares (including applications from Anchor Investors and prior to technical rejections) resulting in 8.8331 times subscription. The details of the applications received in the Offer from various categories are as under (before technical rejections):

Sl no.	Category	No of Applications applied	No. of Equity Shares	Shares Reserved as per Prospectus	No. of times Subscribed	Amount (₹)
A	Anchor Investors	36	8,878,896	8,663,404	1.0249	4,812,361,632
B	Qualified Institutional Bidders (excluding Anchor Investors)	71	223,952,040	5,775,605	38.7755	121,382,005,680
C	Non-Institutional Investors -Upto ₹ 10 Lakhs	4,292	1,851,984	1,443,901	1.2826	1,005,242,238
D	Non-Institutional Investors - Above ₹ 10 Lakhs	4,414	14,755,797	2,887,803	5.1097	7,997,641,974
E	Retail Individual Investors	244,404	8,208,297	10,107,308	0.8121	4,448,913,978
F	Eligible Employee	1,118	86,589	300,000	0.2886	45,482,580
	Total	**254,335**	**257,733,603**	**29,178,021**	**8.8331**	**139,691,648,082**

Final Demand

A summary of the final demand as at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	516	197,100	0.08	197,100	0.08
2	517	9,666	0.00	206,766	0.08
3	518	6,939	0.00	213,705	0.08
4	519	1,647	0.00	215,352	0.08
5	520	42,012	0.02	257,364	0.10
6	521	4,104	0.00	261,468	0.10
7	522	8,181	0.00	269,649	0.11
8	523	1,593	0.00	271,242	0.11
9	524	1,701	0.00	272,943	0.11
10	525	23,247	0.01	296,190	0.12
11	526	3,240	0.00	299,430	0.12
12	527	1,458	0.00	300,888	0.12
13	528	1,998	0.00	302,886	0.12
14	529	7,560	0.00	310,446	0.12
15	530	38,367	0.01	348,813	0.14
16	531	2,673	0.00	351,486	0.14
17	532	4,887	0.00	356,373	0.14
18	533	675	0.00	357,048	0.14
19	534	1,242	0.00	358,290	0.14
20	535	17,280	0.01	375,570	0.15
21	536	2,268	0.00	377,838	0.15
22	537	1,431	0.00	379,269	0.15
23	538	4,590	0.00	383,859	0.15
24	539	1,620	0.00	385,479	0.15
25	540	23,139	0.01	408,618	0.16
26	541	10,341	0.00	418,959	0.16
27	542	243,844,776	95.31	244,263,735	95.47
28	CUTOFF	11,591,667	4.53	255,855,402	100.00
	TOTAL	**255,855,402**	**100.00**		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being NSE on May 5, 2022.

INVESTORS, PLEASE NOTE

The Employee Reservation as per the Prospectus was mentioned in amount terms aggregating to not more than ₹156.60 million, translating to 300,000 Equity Shares at ₹ 522 per Equity Share (after Employee discount of ₹20 per Equity Share). Valid Bids received and considered for Allotment under Employee Category were for 44,118 Equity Shares amounting to ₹ 23.02 million. The unsubscribed portion was adjusted as follows:

Particulars		No. of Equity Shares	Amount (in ₹)
Employee Reservation Portion in ₹ as per Prospectus	A	300,000	156,600,000
Valid Bids considered for allotment	B	44,118	23,029,596
Deficit in ₹.	C = (A-B)	255,882	133,570,404
Deficit in Equity Shares	C / ₹ 522 (after employee discount of ₹ 20 per Equity Share to the Offer Price)		255,882
No. of Shares for Spillover	C / ₹ 542 (Offer Price)		246,440**
Difference in Spillover due to Employee Discount			-9,442

**Unsubscribed portion of Employee Reservation Portion of 246,440 Equity Shares spilled over to QIBs, NIB and Retail Categories in the ratio of 50:15:35.

A. Allotment to Retail Individual Bidders (after technical rejections)

The Basis of Allotment to the Retail Individual Bidders, who have bid at the Cut-Off Price or at the Offer Price of ₹ 542 per Equity Share, was finalized in consultation with NSE. This category has been subscribed to the extent of 0.76967 times (including spillover from Employee category). The total number of Equity Shares Allotted in Retail Portion is 7,845,660 Equity Shares (including spillover of 86,254 Equity Shares from Employee category) to 234,230 successful Retail Individual Bidder. The category-wise details of the Basis of Allotment are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
27	216,596	92.47	5,848,092	74.54	27	1: 1	5,848,092
54	9,314	3.98	502,956	6.41	54	1: 1	502,956
81	2,414	1.03	195,534	2.49	81	1: 1	195,534
108	1,583	0.68	170,964	2.18	108	1: 1	170,964
135	775	0.33	104,625	1.33	135	1: 1	104,625
162	352	0.15	57,024	0.73	162	1: 1	57,024
189	506	0.22	95,634	1.22	189	1: 1	95,634
216	224	0.10	48,384	0.62	216	1: 1	48,384
243	73	0.03	17,739	0.23	243	1: 1	17,739
270	370	0.16	99,900	1.27	270	1: 1	99,900
297	61	0.03	18,117	0.23	297	1: 1	18,117
324	73	0.03	23,652	0.30	324	1: 1	23,652
351	1,889	0.81	663,039	8.45	351	1: 1	663,039
TOTAL	**234,230**	**100.00**	**7,845,660**	**100.00**			**7,845,660**

Unsubscribed portion of 2,261,648 Equity Shares spilled over to QIB and NIB Categories in the ratio of 50:15

B. Allotment to Non-Institutional Bidders (Upto ₹ 10 Lacs) (after technical rejections)

The Basis of Allotment to the Non-Institutional Bidders (**Upto ₹10 Lacs**), who have bid at the Offer Price of ₹ 542 per Equity Share or above, was finalized in consultation with NSE. The Non-Institutional Portion (**Upto ₹ 10 Lacs**), has been subscribed to the extent of 1.11673 times (including spillover from Employee and Retail Individual categories). The total number of Equity Shares Allotted in this category is 1,636,831 Equity Shares (including spillover of 192,930 Equity Shares from Employee and Retail categories) to 4,242 successful Non-Institutional Bidder. The category-wise details of the Basis of Allotment are as under: (Sample)

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
378	3867	91.16	1,461,726	79.97	378	1:1	1,461,726
405	71	1.67	28,755	1.57	382	1:1	27,122
432	13	0.31	5,616	0.31	386	1:1	5,018
459	15	0.35	6,885	0.38	390	1:1	5,850
486	7	0.17	3,402	0.19	394	1:1	2,758
513	4	0.09	2,052	0.11	398	1:1	1,592
540	39	0.92	21,060	1.15	402	1:1	15,678
567	4	0.09	2,268	0.12	406	1:1	1,624
810	11	0.26	8,910	0.49	442	1:1	4,862
837	1	0.02	837	0.05	446	1:1	446
1,350	5	0.12	6,750	0.37	522	1:1	2,610
1,458	7	0.17	10,206	0.56	539	1:1	3,773
1,485	3	0.07	4,455	0.24	543	1:1	1,629
1,512	1	0.02	1,512	0.08	547	1:1	547
1,620	4	0.09	6,480	0.35	563	1:1	2,252
1,701	1	0.02	1,701	0.09	575	1:1	575
1,755	4	0.09	7,020	0.38	583	1:1	2,332
1,809	7	0.17	12,663	0.69	591	1:1	4,137
1,836	81	1.91	148,716	8.14	594	1:1	48,114
					1*	67: 81	67
TOTAL	**4,242**	**100.00**	**1,827,900**	**100.00**			**1,636,831**

* 1 additional Equity Share has been allotted to Category 1,836 in the ratio of 67 : 81

C. Allotment to Non-Institutional Bidders (Above ₹ 10 Lacs) (after technical rejections)

The Basis of Allotment to the Non-Institutional Bidders (**Above ₹ 10 Lacs**), who have bid at the Offer Price of ₹ 542 per Equity Share or above, was finalized in consultation with NSE. The Non-Institutional Portion (**Above ₹ 10 Lacs**) has been subscribed to the extent of 4.47945 times (including spillover of 385,860 Equity Shares from Employee and Retail Individuals categories). The total number of Equity Shares Allotted in this category is 3,273,663 Equity Shares (including spillover from Employee and Retail categories) to 4,365 successful Non- Institutional Bidder. The category-wise details of the Basis of Allotment are as under: (Sample)

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1,863	4022	92.14	74,92,986	51.10	563	1 : 1	22,64,386
					1*	19 : 73	1,047
1,998	1	0.02	1,998	0.01	580	1:1	580
2,025	17	0.39	34,425	0.23	583	1:1	9,911
2,052	1	0.02	2,052	0.01	587	1:1	587
2,106	6	0.14	12,636	0.09	594	1:1	3,564
2,160	4	0.09	8,640	0.06	600	1:1	2,400
13,500	1	0.02	13,500	0.09	2,015	1:1	2,015
13,851	1	0.02	13,851	0.09	2,059	1:1	2,059
16,227	1	0.02	16,227	0.11	2,355	1:1	2,355
16,470	1	0.02	16,470	0.11	2,386	1:1	2,386
92,259	1	0.02	92,259	0.63	11,841	1:1	11,841
100,008	2	0.05	200,016	1.36	12,808	1:1	25,616
110,700	1	0.02	110,700	0.75	14,142	1:1	14,142
184,491	2	0.05	368,982	2.52	23,349	1:1	46,698
184,518	1	0.02	184,518	1.26	23,352	1:1	23,352
196,479	1	0.02	196,479	1.34	24,844	1:1	24,844
276,750	1	0.02	276,750	1.89	34,859	1:1	34,859
461,160	3	0.07	1,383,480	9.43	57,866	1:1	173,598
553,500	1	0.02	553,500	3.77	69,387	1:1	69,387
Total	**4365**	**100.00**	**14,664,213**	**100.00**			**3,273,663**

*1 additional Equity Share has been allotted to Category 1,863 in the ratio of 19 : 73

D. Allotment to Eligible Employee (after technical rejections)

The Basis of Allotment to the Employee Investors, who have bid at the Offer Price of ₹ 542 per Equity Share or above (a discount of ₹ 20 per Equity Share was offered to Eligible Employees bidding under Employee Reservation Portion), was finalized in consultation with NSE. This category has been subscribed to the extent of 0.14706 times. The total number of Equity Shares allotted in this category is 44,118 Equity Shares to 189 successful applicants. The category-wise details of the Basis of Allotment are as under:

Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per applicant	Ratio	Total No. of Equity Shares Allotted
27	39	20.63	1,053	2.39	27	1:1	1,053
54	32	16.93	1,728	3.92	54	1:1	1,728
81	18	9.52	1,458	3.30	81	1:1	1,458
108	10	5.29	1,080	2.45	108	1:1	1,080
135	5	2.65	675	1.53	135	1:1	675
162	5	2.65	810	1.84	162	1:1	810
189	7	3.70	1,323	3.00	189	1:1	1,323
216	5	2.65	1,080	2.45	216	1:1	1,080
243	1	0.53	243	0.55	243	1:1	243
270	5	2.65	1,350	3.06	270	1:1	1,350
297	4	2.12	1,188	2.69	297	1:1	1,188
324	2	1.06	648	1.47	324	1:1	648
351	10	5.29	3,510	7.96	351	1:1	3,510
378	8	4.23	3,024	6.85	378	1:1	3,024
405	4	2.12	1,620	3.67	405	1:1	1,620
486	3	1.59	1,458	3.30	486	1:1	1,458
540	6	3.17	3,240	7.34	540	1:1	3,240
567	9	4.76	5,103	11.57	567	1:1	5,103
675	1	0.53	675	1.53	675	1:1	675
702	1	0.53	702	1.59	702	1:1	702
729	1	0.53	729	1.65	729	1:1	729
756	1	0.53	756	1.71	756	1:1	756
783	1	0.53	783	1.77	783	1:1	783
810	3	1.59	2,430	5.51	810	1:1	2,430
918	4	2.12	3,672	8.32	918	1:1	3,672
945	4	2.12	3,780	8.57	945	1:1	3,780
TOTAL	**189**	**100.00**	**44,118**	**100.00**			**44,118**

Unsubscribed portion of 246,440 Equity Shares spilled over to QIBs, NIB and Retail Categories in the ratio of 50:15:35.

E. Allotment to QIBs (excluding Anchor Investors) (after technical rejections)

Allotment to QIBs, who have Bid at the Offer Price of ₹542 per Equity Share or above, has been done on a proportionate basis in consultation with NSE. This category has been subscribed to the extent of 29.06617 times (including spillover from Employee and Retail Individuals categories). As per the SEBI Regulations, Mutual Funds were Allotted 5% of the Equity Shares of QIB Portion available i.e., 385,246 Equity Shares (including spillover of 96,465 Equity Shares from Employee and Retail categories) and other QIBs and unsatisfied demand of Mutual Funds were Allotted the remaining available Equity Shares i.e., 7,319,657 Equity Shares (including spillover of 1,929,298 Equity Shares from Employee and Retail categories) on a proportionate basis. The total number of Equity Shares Allotted in the QIB Portion is 7,704,903 Equity Shares, which were allotted to 71 successful QIB Bidders. The category-wise details of the Basis of Allotment are as under:

Category	FIs/Banks	FIIs/FPIs	IC	MFs	OTHs	Total
QIB	1,730,953	3,759,816	394,638	740,570	1,078,926	7,704,903

F. Allotment to Anchor Investors

The Company, Dr. Ramesh Kancharla (acting on behalf of the other Promoter Selling Shareholders and the Other Selling Shareholder) and the Investor Selling Shareholders, in consultation with the BRLMs, have allocated 8,663,404 Equity Shares to 23 Anchor Investors (through 36 Applications) at the Anchor Investor Offer Price of ₹ 542 per Equity Share in accordance with the SEBI Regulations. This represents 60% of the QIB Portion.

Category	MFs	ICs	AIFs	FPI/FIIs	Total
Anchor	3,897,396	738,072	369,036	3,658,900	8,663,404

The IPO Committee of our Company on May 5, 2022, has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being NSE and has allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum-Unblocking Intimations and/ or notices has been emailed or dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfer to Public Offer Account has been issued on May 5, 2022, and payment to non-Syndicate brokers have been issued on May 6, 2022. In case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on May 6, 2022 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company has filed the Listing application with NSE and BSE on May 6, 2022. The Company has received listing and trading approval from NSE and BSE and the trading will commence on May 10, 2022.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

INVESTORS, PLEASE NOTE

The details of the allotment made will be hosted on the website of the Registrar to the Offer, **KFin Technologies Limited** at : www.kfintech.com

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:

KFINTECH

EXPERIENCE TRANSFORMATION

KFin Technologies Limited (formerly known as KFin Technologies Private Limited)
Selenium, Tower-B, Plot 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi - 500 032 Telangana, India. Telephone: +91 40 6716 2222
E-mail: rcml.ipo@kfintech.com
Website: www.kfintech.com
Investor Grievance ID: einward.ris@kfintech.com
Contact Person: M Murali Krishna
SEBI Registration Number: INR000000221

For **RAINBOW CHILDREN'S MEDICARE LIMITED**
On behalf of the Board of Directors
Sd/-
Ashish Kapil
Company Secretary and Compliance Officer

Place: Hyderabad, Telangana
Date: May 9, 2022

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF RAINBOW CHILDREN'S MEDICARE LIMITED.

RAINBOW CHILDREN'S MEDICARE LIMITED has filed the Prospectus dated May 2, 2022 with RoC and thereafter with SEBI and Stock Exchanges. The Prospectus is available on the website of SEBI at www.sebi.gov.in, websites of BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively and is available on the websites of the BRLMs, i.e. Kotak Mahindra Capital Company Limited, J.P. Morgan India Private Limited and IIFL Securities Limited at https://investmentbank.kotak.com, www.jpmipl.com and www.iiflcap.com, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, refer to the Prospectus, including the section titled "Risk Factors" of the Prospectus. Specific attention of the investors is invited to "Risk Factors" beginning on page 47 of the Prospectus.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act and referred to in this Prospectus as "U.S. QIBs", for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in this Prospectus as "QIBs") pursuant to Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.